Frontlight ResearchEarly access
Taking people in South KoreaNo phase
Testing CKDB001 for early Alzheimer's disease
Tests the drug CKDB001 in people with early Alzheimer's disease.
Key facts
- Who runs it
- CKD Bio Corporation
- Where
- Gyeonggi-do and Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 23 Feb 2026
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- L. lactis CKDB001
- Placebo
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 85 with early Alzheimer's disease and a positive amyloid PET scan.
- Age
- 55 to 85 years
- Sex
- Men and women can join.
- Disease stage
- Early Alzheimer's disease: K-MMSE score of 20 to 28, global CDR score of 0.5 to 1, and CDR Memory Box score of 0.5 or greater.
- Earlier treatment
- No disease-modifying therapy for Alzheimer's within 1 year before screening. No new or changed dementia symptom treatment within 12 weeks before screening.
- Biomarker or test result
- Positive amyloid on a PET scan.
Main reasons for not taking part
- Other diseases that could affect thinking tests, such as a history of CNS disease
- History of seizure disorder or epilepsy
- Alcohol or substance abuse or dependence
- Cancer diagnosed or recurring within 5 years before screening
- Major cardiovascular event within 12 months before screening
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male and female adults aged ≥55 and ≤85 years at the time of written consent
- Subjects with a Korean Mini-Mental State Examination (K-MMSE) score of 20 to 28
- Have a global Clinical Dementia Rating (CDR) score of 0.5 to 1 and a CDR Memory Box score of 0.5 or greater
- Subjects who test positive for amyloid on Positron Emission Tomography (PET)
Who cannot take part
- History of a major cardiovascular event within 12 months prior to screening
- Severe or active infectious disease requiring treatment with antibiotics or antivirals within 4 weeks prior to randomization, or expected to require such treatment during the study period
- Clinically significant gastrointestinal disorders within 3 months prior to screening, or conditions that may lead to malabsorption
- Treatment with any disease-modifying therapy for Alzheimer's disease within 1 year prior to screening
- Initiation or dosage/regimen changes of symptomatic treatments for dementia within 12 weeks prior to screening
- Chronic use of medications acting on the CNS or those that may affect cognitive function within 8 weeks prior to screening
- Regular use of medications that may alter the gut microbiota within 4 weeks prior to screening
- Subjects with clinically significant diseases other than Alzheimer's disease that may confound cognitive assessment; History of central nervous system (CNS) diseases; Active central nervous system (CNS) infection capable of affecting cognitive function, or a history of infection resulting in neurological sequelae; Structural brain abnormalities identified on screening MRI that could account for cognitive impairment; Abnormal thyroid function identified at screening; Vitamin B12 deficiency identified at screening
- History of seizure disorder or epilepsy
- History of psychiatric disorders, including schizophrenia, bipolar disorder, or clinically significant major depressive disorder, with current active symptoms
- History of malignancy diagnosed or recurrent within 5 years prior to screening
- Cardiovascular disease requiring the administration of anticoagulants
- History or suspicion of alcohol or substance abuse/dependence
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
Where in South Korea
- Yonsei University Yongin Severance HospitalGyeonggi-do, South KoreaContact: Bisong KimTaking people
- Yonsei University Severance HospitalSeoul, South KoreaContact: Bisong KimTaking people
About the trial
What the trial wants to find out
Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
The 2 groups in the trial
- L. lactis CKDB001Existing treatment, for comparison
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
- Plain-language title
- Testing CKDB001 for early Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07496021, who can take part
- Record updated
- 30 March 2026